- OncoTree
- CUPNOS
Loading cancer entity…
Loading cancer entity…
Clinical trials
8 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors(ANTARES) | recruiting | Phase 2 | 28 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07434180 | Phase II Trial of Lu-177 FAP-2286 in Patients With Carcinoma of Unknown Primary(Lu-FAP CUP) | not yet recruiting | Phase 2 | 20 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 25, 2026 |
| clinicaltrials |
| NCT06869174 | Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary | not yet recruiting | Phase 2 | 50 | Zhiguo Luo, MD, PhDOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04848597 | PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP | unknown | Phase 2 | 48 | Fudan UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05241132 | Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary | unknown | Phase 2 | 27 | Wei XuOTHER | 1 | Feb 15, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Apr 15, 2026source: clinicaltrials